Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 5/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | TAF1 | P21675 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972143 | 0.87 | PTPN7 (0.56) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL9964598 | 0.86 | BRD4 (0.55) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL15082471 | 0.85 | AURKA (0.57) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL738237 | 0.85 | HTR4 (0.53) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL22280231 | 0.83 | LRRK2 (0.55) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL21473640 | 0.83 | PTK2 (0.56) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL14817995 | 0.82 | UTS2R (0.48) | KMT2A | |
| SCHEMBL13880647 | 0.82 | AURKA (0.52) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL736393 | 0.81 | SIRT6 (0.52) | AURKAAURKBLRRK2ROCK2ROCK1 | |
| SCHEMBL444453 | 0.81 | KMT2A (0.44) | BRD4TAF1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417125-B1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-09-09 | — | — | EP | disclosed |
| US-8772280-B2 | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-8772280-B2 | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-20120065192-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065192-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065192-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | PHKG1, PPM1A, PRKAG1 | AURKA 430/4885AURKB 349/4885LRRK2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.